NEW YORK, Aug. 23 /PRNewswire-FirstCall/ -- Xenomics, Inc. (the “Company”) a developer of next-generation medical DNA diagnostic technologies, today announced that Dr. Samuil Umansky, MD, Ph.D., Xenomics’ Chief Scientific Officer and Co-Founder, has been invited to make a presentation regarding the Company’s proprietary transrenal nucleic acid (Tr-NA) technology at the 5th International Symposium on Circulating Nucleic Acids in Plasma and Serum (CNAPS-5) in Moscow, Russia.
Dr. Umansky’s presentation entitled “Transrenal Nucleic Acids: From Proof-of-Principle to Clinical Tests” will describe the most recent achievements in Tr-DNA/RNA technology and development of specific tests.
The CNAPS meetings, held every two years, are devoted to a new direction in molecular diagnostics, the use of nucleic acids from bodily fluids such as plasma and urine for development of clinical tests. These tests can be used for diagnosis and monitoring of pathologies, including prenatal diagnostics, oncology, organ transplantation, infectious diseases, and others. CNAPS meetings include forums of professionals and leaders in the field of cell-free circulating nucleic acids and their practical applications. Additional information is available at www.cnaps5moscow.ru.
Dr. Umansky will present data on practical applications of new methods of Tr-NA isolation and use of “ultrashort” PCR amplicons for developing prenatal tests, as well as tests in areas of oncology and infectious diseases. He will also discuss how new techniques for Tr-NA purifications led to the discovery of both ubiquitous and transrenal tissue-specific microRNA (miRNA) in the urine. Qualitative and quantitative analysis of urinary miRNA significantly expands diagnostic applications of the Xenomics proprietary Tr-NA technology.
Xenomics’ proprietary Tr-NA technology utilizes urine samples, rather than invasive blood or other samples. Fragmented cellular DNA, RNA, and whole miRNA from throughout the body cross the kidney barrier and accumulate in the urine providing vital information about a wide range of conditions inside the body. The Company believes this new technology will foster fundamental improvements in safety, accuracy and functionality of testing in the field of molecular diagnostics, currently a $1.5 billion segment of the healthcare industry.
About Xenomics, Inc.
Xenomics is a molecular diagnostics company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics’ patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a European patent for the Company’s prenatal testing applications, and numerous pending patent applications. For more investor-specific information, including daily and historical Company stock quote data, recent news releases and an Investor Fact Sheet, please visit http://www.xenomics.com. Xenomics is also listed on the Frankfurt Stock Exchange under the symbol XE7.
Forward-Looking Statements
Certain statements made in this press release are forward-looking. Such statements are indicated by words such as “expect,” “might,” “should,” “anticipate” and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in Xenomics’ Form 10-KSB as filed with the Securities and Exchange Commission on May 16, 2006 and its other periodic reports, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics’ technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.
Contact: Samuil Umansky +1-732-438-8290
Xenomics, Inc.
CONTACT: Samuil Umansky, +1-732-438-8290, for Xenomics, Inc.
